Article
Hematology
Feiqiong Gao, Jiawei Zhang, Jianlai Hu, Liming Lin, Yang Xu
Summary: This meta-analysis compared the use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in allogeneic hematopoietic stem cell transplantation (allo-HCT). The results showed that PTCy was associated with lower incidence of aGVHD and NRM compared to ATG, along with better overall survival and progression-free survival, without significant differences in relapse rate and cGVHD incidence. More prospective randomized trials are needed to further validate these findings.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Zhenyang Gu, Qian Xiong, Lu Wang, Lili Wang, Fei Li, Cheng Hou, Liping Dou, Baoli Zhu, Daihong Liu
Summary: This study indicates that gut dysbiosis in platforms of ATG-based myeloablative allo-HCT features loss of bacterial diversity. The diversity of the intestinal flora at the engraftment period is an independent predictor of longer survival.
Article
Hematology
Yanming Zhang, Limin Liu, Yejun Si, Miao Miao, Huiying Qiu, Xiaowen Tang, Yue Han, Chengcheng Fu, Zhengming Jin, Suning Chen, Aining Sun, Depei Wu
Summary: In comparing ATG-F and p-ALG as part of the conditioning regimen in HSCT for SAA patients, the study found no significant differences in transplant complications and patient survival rates between the two treatments.
Article
Oncology
Dipenkumar Modi, Samer Alkassis, Seongho Kim, Andrew Kin, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: We retrospectively evaluated allogeneic stem cell transplant (alloSCT) outcomes of 86 adult ALL patients in complete remission (CR) who received TBI-containing reduced intensity (RIC) and myeloablative conditioning (MAC). The study found no significant difference in survival rate between the RIC and MAC groups, but the MAC group had a lower relapse rate.
LEUKEMIA & LYMPHOMA
(2023)
Article
Immunology
Joanne E. Davis, Kelei Du, Mandy J. Ludford-Menting, Ashvind Prabahran, Eric Wong, Nicholas D. Huntington, Rachel M. Koldej, David S. Ritchie
Summary: The study explores the repurposed use of ruxolitinib or venetoclax as pre-transplant immune-modulators to promote the efficacy of alloSCT, while reducing its toxicity. The research shows that JAK1/2 and BCL-2 modulation can lower the barrier to donor engraftment and enhance the GVT effect in alloSCT. The different mechanisms of action of these drugs on immune cell subsets and gene expression regulation signify varying rates of GVHD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Hong Wang, Qingyuan Wang, Jiaqian Qi, Xueqian Li, Tiantian Chu, Huiying Qiu, Chengcheng Fu, Xiaowen Tang, Changgeng Ruan, Depei Wu, Yue Han
Summary: The study aimed to evaluate the impact of different pre-transplant therapies and transplantation interval times on the prognosis of patients with myelodysplastic syndromes (MDS). The results showed that there were no significant differences in overall survival (OS) and relapse-free survival (RFS) between patients who received hypomethylating agents (HMAs) or supportive care (SC), except for a lower rate of non-relapse mortality in the HMA-treated group. Compared to patients who received HMA, those who received chemotherapy-based therapy had a lower OS rate and a slightly higher non-relapse mortality rate. The early transplant group (transplant interval <6 months) had better OS and lower non-relapse mortality compared to the delayed transplant group (transplant interval >= 6 months).
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biophysics
Remy Dulery, Claire Goudet, Daniele Mannina, Antonio Bianchessi, Angela Granata, Samia Harbi, Valerio Maisano, Christian Chabannon, Florent Malard, Eolia Brissot, Simona Sestili, Anne Banet, Zoe van de Wyngaert, Ramdane Belhocine, Stephane Ederhy, Luca Castagna, Stefania Bramanti, Didier Blaise, Mohamad Mohty, Sabine Fuerst, Raynier Devillier
Summary: Comparing the outcomes of PT-Cy at 80 mg/kg and 100 mg/kg in elderly patients undergoing haploidentical HCT, it was found that reducing the PT-Cy dose to 80 mg/kg improved hematological recovery and reduced the incidence of hemorrhagic cystitis.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Wenli Zhang, Ruirui Gui, Yingling Zu, Binglei Zhang, Zhen Li, Yanli Zhang, Xianjing Wang, Shuli Guo, Xinrong Zhan, Yuewen Fu, Yongping Song, Jian Zhou
Summary: This study demonstrates that the combination of reduced-dose post-transplant cyclophosphamide (PTCy) and low-dose post-transplant anti-thymocyte globulin (ATG) in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) significantly reduces the incidence of graft-versus-host disease (GVHD) and improves overall survival and disease-free survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Jeongmin Seo, Dong-Yeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Ja Min Byun, Junshik Hong
Summary: The study found that patients with low preconditioning ALC levels (<500/mu l) undergoing MUD alloSCT with RIC and ATG had shorter overall survival and higher infectious mortality. However, preconditioning ALC did not significantly affect the incidence of acute GVHD, moderate-severe chronic GVHD, or relapse rates.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Article
Hematology
Jianli Xu, Wenyan Miao, Hailong Yuan, Ying Liu, Gang Chen, Hongbo Wang, Gulibadanmu Aizezi, Jianhua Qu, Xianlin Duan, Ruixue Yang, Maliya Muhashi, Chunxia Han, Linglu Ding, Nadiya Abulaiti, Nannan Pang, Le Zhang, Ming Jiang
Summary: Using high-dose non-TCD in vitro PBSCs as the graft source along with enhanced GVHD prophylaxis, this study demonstrates an effective treatment for hematologic malignancies.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Biophysics
Nobuhiko Imahashi, Seitaro Terakura, Eisei Kondo, Koji Kato, Sung-Won Kim, Akihito Shinohara, Mizuki Watanabe, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi, Jun Ishikawa, Keisuke Kataoka, Souichi Shiratori, Takashi Ikeda, Ken-ichi Matsuoka, Shuro Yoshida, Tadakazu Kondo, Takafumi Kimura, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
Summary: The study showed that UCB transplantation with optimal conditioning and GVHD prophylaxis had better outcomes compared to MRD and MUD transplantation, suggesting it is a highly effective treatment for mature lymphoid malignancies. This indicates that UCB transplantation might be preferred over MRD or MUD transplantation in certain settings.
BONE MARROW TRANSPLANTATION
(2022)
Article
Immunology
Guangyang Weng, Zhiping Fan, Huiwen Xue, Fen Huang, Na Xu, Hua Jin, Sijian Yu, Zhixin Ye, Jingchao Fan, Li Xuan, Qifa Liu
Summary: The study found that haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome (BOS) compared to HLA-matched sibling donor stem cell transplantation. Additionally, the use of antithymocyte globulin (ATG) and mixed grafts may be protective factors in reducing the incidence of BOS.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Uzma Zaidi, Mushkbar Fatima, Shafaq Abdul Samad, Kashif Shafique, Hira Fatima Waseem, Tasneem Farzana, Tahir Sultan Shamsi
Summary: This study analyzes the success of allogeneic hematopoietic stem cell transplant in aplastic anemia patients. The findings suggest that the Flu/Cy conditioning regimen can be a suitable alternative for developing countries with limited healthcare resources.
STEM CELLS INTERNATIONAL
(2022)
Article
Oncology
Saori Oku, Toshiko Futatsuki, Yoshiko Imamura, Haruna Hikita, Akemi Inada, Shinsuke Mizutani, Yasuo Mori, Haruhiko Kashiwazaki
Summary: This study found that cryotherapy can effectively prevent oral mucositis (OM) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, especially in cases without methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Hematology
Dipenkumar Modi, Vijendra Singh, Seongho Kim, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: When comparing outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning and myeloablative conditioning regimens using thymoglobulin for GVHD prophylaxis, there was no significant difference in survival, relapse rates, or GVHD-free relapse-free survival between the two regimens. Thymoglobulin at 4.5 mg/kg did not have any adverse impact on survival when used with the reduced intensity conditioning regimen.
ANNALS OF HEMATOLOGY
(2021)